Jennison Associates LLC acquired a new position in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 264,889 shares of the biotechnology company's stock, valued at approximately $8,874,000. Jennison Associates LLC owned about 0.97% of AnaptysBio at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently modified their holdings of ANAB. Frazier Life Sciences Management L.P. grew its holdings in AnaptysBio by 140.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company's stock worth $54,270,000 after purchasing an additional 1,265,891 shares during the period. Assenagon Asset Management S.A. boosted its stake in shares of AnaptysBio by 55.1% during the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company's stock worth $15,927,000 after acquiring an additional 168,813 shares during the period. Victory Capital Management Inc. increased its holdings in shares of AnaptysBio by 677.9% during the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company's stock worth $7,948,000 after acquiring an additional 206,750 shares during the last quarter. Renaissance Technologies LLC raised its stake in AnaptysBio by 52.4% in the 2nd quarter. Renaissance Technologies LLC now owns 152,702 shares of the biotechnology company's stock valued at $3,827,000 after acquiring an additional 52,502 shares during the period. Finally, Ensign Peak Advisors Inc lifted its holdings in AnaptysBio by 74.4% during the 2nd quarter. Ensign Peak Advisors Inc now owns 75,755 shares of the biotechnology company's stock valued at $1,898,000 after purchasing an additional 32,313 shares during the last quarter.
Several equities analysts have commented on the stock. Wedbush reiterated an "outperform" rating and issued a $42.00 price objective on shares of AnaptysBio in a report on Thursday, November 14th. Guggenheim upped their price target on shares of AnaptysBio from $75.00 to $90.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Truist Financial raised their price objective on shares of AnaptysBio from $20.00 to $30.00 and gave the stock a "hold" rating in a research report on Thursday, August 15th. UBS Group upped their target price on AnaptysBio from $23.00 to $33.00 and gave the company a "neutral" rating in a research report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. dropped their price target on AnaptysBio from $75.00 to $66.00 and set an "overweight" rating for the company in a report on Tuesday, November 12th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $54.64.
Check Out Our Latest Stock Analysis on ANAB
AnaptysBio stock opened at $22.27 on Friday. The stock's 50 day moving average is $29.78 and its 200 day moving average is $29.71. AnaptysBio, Inc. has a one year low of $13.36 and a one year high of $41.31. The firm has a market cap of $677.65 million, a P/E ratio of -3.49 and a beta of -0.24.
AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.72) by $0.58. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. The firm had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. Equities analysts anticipate that AnaptysBio, Inc. will post -6.02 earnings per share for the current fiscal year.
In other news, insider Eric J. Loumeau sold 8,720 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.82, for a total transaction of $347,230.40. Following the transaction, the insider now owns 7,020 shares of the company's stock, valued at $279,536.40. This represents a 55.40 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Dennis Mulroy sold 12,220 shares of the business's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the completion of the sale, the chief financial officer now directly owns 4,744 shares of the company's stock, valued at $189,333.04. The trade was a 72.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,440 shares of company stock worth $892,936 over the last quarter. Company insiders own 33.70% of the company's stock.
AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider AnaptysBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AnaptysBio wasn't on the list.
While AnaptysBio currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.